The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1764
September 28, 2026
View Complete Issue         Table of Contents 2019 
Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
September 28, 2026 (Issue: 1764)
The FDA has approved daraxonrasib (Rasonque – Revolution Medicines), an oral RAS GTPase multi-selective inhibitor, for treatment of metastatic pancreatic adenocarcinoma, regardless of RAS G12 mutation status, in adults who received at least one...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
Article code: 1764b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.